IE
RCKT icon

Israel Englander’s Rocket Pharmaceuticals RCKT Stock Holding History

Israel Englander’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$887K – 7003
2021
Q1 		$887K Buy
+20,000
New +$1.1M ﹤0.01% 4337

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's RCKT Position: Q2 2026 in Review

Israel Englander increased its Rocket Pharmaceuticals (RCKT) stake by 28% in Q2 2026, buying an estimated $2.93M and bringing the position to 4,000,344 shares worth $13.7M. The position accounts for 0.01% of the portfolio, ranked #1986.

Israel Englander first reported a position in RCKT in Q4 2015 and has held it in 36 quarters since. The position peaked at $22.2M in Q3 2024. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Israel Englander held 4,000,344 shares of Rocket Pharmaceuticals worth $13.7M as of Q2 2026.
  • Israel Englander bought 882,220 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.93M.
  • Rocket Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1986 holding.
  • Israel Englander first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 36 quarters since.
  • Israel Englander's Rocket Pharmaceuticals position peaked at $22.2M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.